Pliva ANDA Approvals On Hold Following FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Deliveries will not be interrupted by GMP violations at Zagreb, Croatia facility, Pliva says.
You may also be interested in...
Two Pliva ANDAs Approved Following Lifting of FDA Hold
The Croatian firm will launch generic azithromycin imminently, having resolved manufacturing issues at its Zagreb plant.
Two Pliva ANDAs Approved Following Lifting of FDA Hold
The Croatian firm will launch generic azithromycin imminently, having resolved manufacturing issues at its Zagreb plant.
Actavis Ups Bid For Pliva, Topping Barr’s Overture
Actavis' $2.3 bil. bid surpasses a previous $2.2 bil. Barr offer for the Croatian generics firm.